Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Multiple Myeloma
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
58%
Acute Myeloid Leukemia
41%
Granulocyte Colony-stimulating Factor (G-CSF)
33%
Phase I Study
27%
Overall Survival
25%
Relapsed/refractory multiple Myeloma
25%
Hematopoietic Cell Transplantation
24%
Chronic Graft-versus-host Disease (cGVHD)
22%
Lenalidomide
20%
COVID-19
19%
Bortezomib
19%
Myelodysplastic Syndrome
19%
Complete Remission
18%
High Risk
17%
Chemotherapy
17%
High Dose
17%
Cyclophosphamide
17%
Plerixafor
17%
Non-Hodgkin Lymphoma
16%
Autologous Stem Cell Transplantation (auto-SCT)
16%
High-dose Therapy
15%
High-dose Chemotherapy
15%
Transplantation
15%
Hematological Malignancies
15%
NCCN Guidelines
15%
95% Confidence Interval
14%
Myeloma
14%
Etoposide
14%
Leukemia
14%
Autologous Transplantation
13%
Peripheral Blood Progenitor Cells
13%
Overall Response Rate
13%
Event-free Survival
13%
Pomalidomide
13%
Carmustine
12%
Daratumumab
12%
Graft-versus-host Disease (GvHD)
12%
Carfilzomib
12%
Natural Killer Cells
11%
CD34+ Cells
11%
Engraftment
11%
Hematopoietic Stem Cells
11%
Melphalan
11%
Phase II Trial
10%
Patients with Cancer
10%
CD34+
10%
Progression-free Survival
10%
Metastatic Breast Cancer
10%
Allogeneic Transplantation
10%
Medicine and Dentistry
Multiple Myeloma
85%
Hematopoietic Cell
51%
Cell Transplantation
38%
Acute Myeloid Leukemia
29%
Chemotherapy
28%
Drug Megadose
24%
Diseases
20%
Overall Survival
20%
Malignant Neoplasm
19%
COVID-19
19%
Myelodysplastic Syndrome
16%
Carmustine
14%
Granulocyte Colony Stimulating Factor
14%
Dexamethasone
14%
Non-Hodgkin Lymphoma
14%
High Dose Chemotherapy
13%
Etoposide
13%
Myeloma
13%
Cyclophosphamide
11%
Stem Cell Transplant
11%
Plerixafor
10%
Daratumumab
9%
Progenitor Cell
9%
Oncology
9%
Hematologic Malignancy
8%
Stem Cell Mobilization
8%
Melphalan
8%
Allograft
8%
Metastatic Breast Cancer
8%
Progression Free Survival
8%
Autotransplantation
8%
Breast Cancer
7%
Event Free Survival
7%
Graft Versus Host Reaction
7%
Salvage Therapy
7%
Cytarabine
7%
Infection
7%
Stem Cell Therapy
7%
Stem Cell
7%
Bortezomib
7%
Decitabine
7%
Cardio-Oncology
7%
Azacitidine
7%
Median Follow Up
7%
Smouldering Myeloma
6%
Whole Body Radiation
6%
Immunoglobulin Idiotype
6%
Amyloidosis
6%
Allogeneic Stem Cell Transplantation
6%
Comorbidity
6%
Immunology and Microbiology
Hematopoietic Cell
70%
Multiple Myeloma
53%
Cell Transplantation
51%
Myeloid
29%
Drug Megadose
28%
CD34
24%
Stem Cell
22%
Granulocyte Colony-Stimulating Factor
22%
Overall Survival
21%
Dexamethasone
20%
Cyclophosphamide
19%
Graft-Versus-Host Disease
18%
COVID-19
16%
Engraftment
16%
Plerixafor
15%
Allograft
12%
Natural Killer Cell
12%
Progression Free Survival
10%
Autotransplantation
10%
Chronic Graft Versus Host Disease
9%
Event Free Survival
9%
Acute Graft Versus Host Disease
8%
Allogeneic Stem Cell Transplantation
8%
Daratumumab
8%
Lenalidomide
7%
Pomalidomide
7%
Elotuzumab
7%
Dendritic Cell
7%
Amyloidosis
7%
Infectious Disease
7%
Infection
7%
Apheresis
6%
Immunoglobulin Producing Cell
6%
Cytomegalovirus
6%
Light Chain
6%
Prednisone
6%
Idiotype
6%
Bone Marrow Transplantation
6%
AL Amyloidosis
5%
Hematopoietic Stem Cell Transplantation
5%
Granulocyte
5%
CD8
5%
Cardiovascular System
5%